# Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

> **NCT02876081** · PHASE2 · WITHDRAWN · sponsor: **Fondation Hôpital Saint-Joseph**

## Conditions studied

- SMALL CELL LUNG CARCINOMA

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02876081
- **Lead sponsor:** Fondation Hôpital Saint-Joseph
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-01
- **Primary completion:** 2017-09-01
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** medical decision
- **Last updated:** 2017-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876081, "Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02876081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*